Impact of European Union label changes to avoid inadvertent use of medicinal products containing methotrexate for once‐weekly administration: A survey amongst prescribers, pharmacists and patients on awareness, knowledge, and behaviour

Abstract

AbstractPurposeTo determine the effectiveness of risk minimisation measures (RMM) to avoid inadvertent daily instead of weekly methotrexate (MTX) use, introduced by the European Medicines Agency (EMA) from 2019 onwards.MethodsUsing a cross‐sectional online survey in France, Greece, Germany, Poland, and Sweden in 2022, we assessed awareness, knowledge, and self‐declared behaviour for respondents who prescribed, dispensed, or used once‐weekly MTX in the last 3 months. Respondents' answers were considered as ‘successful’ with regards to RMM effectiveness (vs. unsuccessful) if they provided correct (‘desirable’) responses to 100% of questions regarding awareness and self‐declared behaviour and correct responses to ≥80% of questions about knowledge. Per target population, an outcome was considered successful if achieved by ≥80% of respondents. Effectiveness of RMM was defined by ≥80% being successful on all outcomes.ResultsOne‐hundred‐fifty‐one prescribers, 150 pharmacists, and 150 patients completed the survey. Success rates were 56% (95% CI 48.0%–64.3%) for awareness, 42% (95% CI 34.4%–50.7%) for knowledge, and 31% (95% CI 23.8%–39.2%) for self‐declared behaviour among prescribers, 18% (95% CI 12.8%–25.8%) for awareness, 7% (95% CI 3.7%–12.7%) for knowledge, and 50% (95% CI 41.7%–58.3%) for self‐declared behaviour among pharmacists, and 29% (95% CI 21.6%–36.6%) for awareness, and 3% (95% CI 1.1%–7.6%) for knowledge among patients. Overall success was not attained by any target population.ConclusionsRMM were evaluated as not effective across outcomes of awareness, knowledge, and self‐declared behaviour in prescribers, pharmacists, and patients. Findings suggested we need continued efforts for RMM across all target populations and across all outcomes.